Scholar Rock Holding Corporation
SRRKHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeScholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating. With a market capitalization of $5.05B, it sits in mid-cap territory. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Market Cap
$5.05B
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-16.72
EPS (TTM)
$-3.24
EPS (Fwd)
$-2.48
ROE
-167.8%
ROA
-58.8%
Cash
$492.1M
Total Debt
$203.8M
Free CF
-$153.9M
52W Change
39.8%
Annual Financials
Cash vs Debt
Where SRRK stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SRRK finished 18.36% below its 150-day moving average ($49.29) and 16.57% below its 200-day moving average ($48.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRRK overbought or oversold?
At the October 20, 2026 close, SRRK's RSI(14) was 20.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Scholar Rock Holding Corporation holds $492.1M in cash against $203.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$153.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -167.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.8M (2021) to $0 (2025), a 100% decline worth watching.
SRRK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SRRK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.